Alessandro Maria Vannucchi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/361333/publications.pdf

Version: 2024-02-01

611 papers	35,136 citations	3874 91 h-index	5347 170 g-index
616 all docs	616 docs citations	616 times ranked	14611 citing authors

#	Article	IF	Citations
1	Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Annals of Hematology, 2022, 101, 139-146.	0.8	17
2	Association of Platelet Thromboxane Inhibition by Lowâ€Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. Clinical Pharmacology and Therapeutics, 2022, 111, 939-949.	2.3	6
3	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Advances, 2022, 6, 373-375.	2.5	34
4	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2022, 97, E35.	2.0	18
5	Second versus first wave of COVID-19 in patients with MPN. Leukemia, 2022, 36, 897-900.	3.3	7
6	ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Blood Advances, 2022, 6, 2927-2931.	2.5	20
7	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. Antioxidants, 2022, 11, 113.	2.2	6
8	Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. Liver International, 2022, 42, 419-424.	1.9	4
9	A randomized phase 3 trial of interferon-Î± vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 139, 2931-2941.	0.6	45
10	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer Journal, 2022, 12, 28.	2.8	31
11	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances, 2022, 6, 1162-1174.	2.5	10
12	Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives. International Journal of Hematology, 2022, 115, 626-644.	0.7	12
13	Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. American Journal of Hematology, 2022, 97, 846-855.	2.0	9
14	1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events. Blood Advances, 2022, 6, 3835-3839.	2.5	4
15	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	2.2	46
16	A blood drop through the pore: nanopore sequencing in hematology. Trends in Genetics, 2022, 38, 572-586.	2.9	2
17	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinaseâ€2 (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts. British Journal of Haematology, 2022, 198, 317-327.	1.2	18
18	Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncology, 2022, 18, 2393-2402.	1.1	14

#	Article	IF	Citations
19	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematology,the, 2022, 9, e480-e492.	2.2	18
20	Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Advances, 2022, 6, 5750-5762.	2.5	20
21	Concomitant <scp>JAK2</scp> mutated myeloproliferative neoplasms and hereditary hemochromatosis. International Journal of Laboratory Hematology, 2022, 44, 999-1000.	0.7	1
22	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
23	SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. American Journal of Hematology, 2022, 97, .	2.0	9
24	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia, 2021, 35, 1197-1202.	3.3	9
25	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia, 2021, 35, 2371-2381.	3.3	17
26	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia, 2021, 35, 1121-1133.	3.3	61
27	BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. Tumori, 2021, 107, NP28-NP32.	0.6	0
28	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia, 2021, 35, 485-493.	3.3	70
29	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. American Journal of Human Genetics, 2021, 108, 284-294.	2.6	12
30	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer Journal, 2021, 11, 21.	2.8	26
31	Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 211-212.	1.4	9
32	Lenalidomide: A doubleâ€edged sword for concomitant multiple myeloma and postâ€essential thrombocythemia myelofibrosis. American Journal of Hematology, 2021, 96, 749-754.	2.0	3
33	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. Blood Cancer Journal, 2021, 11, 53.	2.8	24
34	Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. British Journal of Haematology, 2021, 193, 845-848.	1.2	6
35	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	2.5	8
36	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	2.2	79

#	Article	IF	Citations
37	Extreme thrombocytosis in lowâ€risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. American Journal of Hematology, 2021, 96, E182-E184.	2.0	11
38	Ventricular tachyarrhythmias and sudden cardiac death in lightâ€chain amyloidosis: a clash of cardioâ€toxicities?. British Journal of Haematology, 2021, 193, e27-e31.	1.2	5
39	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. HemaSphere, 2021, 5, e553.	1.2	7
40	Mutations and thrombosis in essential thrombocythemia. Blood Cancer Journal, 2021, 11, 77.	2.8	26
41	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. HemaSphere, 2021, 5, e562.	1.2	20
42	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 2021, 17, 1449-1458.	1.1	31
43	Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience. Journal of Clinical Medicine, 2021, 10, 1684.	1.0	19
44	Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs. Blood Advances, 2021, 5, 2184-2195.	2.5	12
45	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia, 2021, 35, 3455-3465.	3.3	25
46	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia, 2021, 35, 2989-2993.	3.3	34
47	Venetoclax with azacitidine or decitabine in blastâ€phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789.	2.0	46
48	T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker. Cancers, 2021, 13, 3102.	1.7	7
49	Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e850-e852.	0.2	2
50	Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer Journal, 2021, 11, 115.	2.8	9
51	Pregnancy in patients with myelofibrosis: Mayoâ€“Florence series of 24 pregnancies in 16 women. British Journal of Haematology, 2021, 195, 133-137.	1.2	2
52	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System lowâ€, intermediateâ€1â€, intermediateâ€2â€, and highâ€risk myelofibrosis in JUMP, a Phase 3b, expandedâ€access study. Hematological Oncology, 2021, 39, 558-566.	0.8	11
53	The EHA Research Roadmap: Malignant Myeloid Diseases. HemaSphere, 2021, 5, e635.	1.2	2
54	Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 2021, 10, 1962.	1.8	11

#	Article	IF	Citations
55	Impaired response to first <scp>SARSâ€CoV</scp>â€2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. American Journal of Hematology, 2021, 96, E408-E410.	2.0	30
56	JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. Journal of Clinical Medicine, 2021, 10, 3752.	1.0	7
57	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. American Journal of Hematology, 2021, 96, 1472-1480.	2.0	20
58	Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. Journal of Clinical Oncology, 2021, 39, 2881-2892.	0.8	59
59	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. Cancers, 2021, 13, 4744.	1.7	9
60	Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia, 2021, 35, 3339-3351.	3.3	57
61	Cerebral venous thrombosis and myeloproliferative neoplasms: A threeâ€center study of 74 consecutive cases. American Journal of Hematology, 2021, 96, 1580-1586.	2.0	13
62	AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance â€“ÂMYNERVA-GIMEMA AML1919 trial. Future Oncology, 2021, 17, 3787-3796.	1.1	0
63	The safety of JAK kinase inhibitors for the treatment of myelofibrosis. Expert Opinion on Drug Safety, 2021, 20, 139-154.	1.0	10
64	hGATA1 Under the Control of a Î¼LCR/Î²-Globin Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced by the Gata1low Mutation in Mice. Frontiers in Genetics, 2021, 12, 720552.	1.1	1
65	Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. International Review of Cell and Molecular Biology, 2021, 365, 1-69.	1.6	13
66	Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRÎ±, PDGFRÎ², FGFR1 or PCM1-JAK2. Biomarker Research, 2021, 9, 83.	2.8	1
67	JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer Journal, 2021, 11, 199.	2.8	47
68	Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. American Journal of Hematology, 2020, 95, E23-E26.	2.0	8
69	Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. Leukemia, 2020, 34, 1208-1209.	3.3	1
70	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	2.0	53
71	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	2.0	8
72	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)â€”a study of 1084 patients. Leukemia, 2020, 34, 1407-1421.	3.3	68

#	Article	IF	Citations
73	Second cancers in MPN: Survival analysis from an international study. American Journal of Hematology, 2020, 95, 295-301.	2.0	34
74	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. Blood Cancer Journal, 2020, 10, 100.	2.8	19
75	How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italyâ€"a GIMEMA MPN WP survey. Leukemia, 2020, 34, 2805-2808.	3.3	16
76	Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data . OncoTargets and Therapy, 2020, Volume 13, 12367-12382.	1.0	39
77	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Advances, 2020, 4, 3063-3071.	2.5	7
78	The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVIDâ€19. International Journal of Laboratory Hematology, 2020, 42, e270-e273.	0.7	8
79	Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARSâ€CoVâ€2 infection. Immunology, 2020, 161, 345-353.	2.0	68
80	COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. Leukemia, 2020, 34, 2813-2814.	3.3	16
81	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 2020, 4, 3677-3687.	2.5	51
82	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Advances, 2020, 4, 5825-5835.	2.5	60
83	Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis. Frontiers in Oncology, 2020, 10, 584541.	1.3	4
84	Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood, 2020, 135, 287-292.	0.6	34
85	To be, or not to be. Blood, 2020, 135, 1617-1618.	0.6	3
86	Polycythemia vera: the current status of preclinical models and therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 615-628.	1.5	5
87	An agenda for future research projects in polycythemia vera and essential thrombocythemia. Haematologica, 2020, 105, 1999-2003.	1.7	6
88	Genetic lesions disrupting calreticulin 3â€²â€untranslated region in <scp>JAK2</scp> mutationâ€negative polycythemia <scp>vera</scp>. American Journal of Hematology, 2020, 95, E263.	2.0	9
89	Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. Blood Advances, 2020, 4, 2477-2488.	2.5	15
90	Î²3-Adrenoreceptor Blockade Reduces Hypoxic Myeloid Leukemic Cells Survival and Chemoresistance. International Journal of Molecular Sciences, 2020, 21, 4210.	1.8	8

#	Article	IF	Citations
91	Current management strategies for polycythemia vera and essential thrombocythemia. Blood Reviews, 2020, 42, 100714.	2.8	35
92	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure. American Journal of Hematology, 2020, 95, 594-603.	2.0	96
93	Primary analysis of JUMP, a phase 3b, expandedâ€access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. British Journal of Haematology, 2020, 189, 888-903.	1.2	61
94	Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer Journal, 2020, 10, 21.	2.8	35
95	The new WHO classification for essential thrombocythemia calls for revision of available evidences. Blood Cancer Journal, 2020, 10, 22.	2.8	19
96	Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. Clinical and Experimental Medicine, 2020, 20, 313-320.	1.9	5
97	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematology,the, 2020, 7, e226-e237.	2.2	93
98	Stem cell transplant for the treatment of myelofibrosis. Expert Review of Hematology, 2020, 13, 363-374.	1.0	4
99	Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia, 2020, 34, 2234-2237.	3.3	34
100	Mutationâ€enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British Journal of Haematology, 2020, 189, 291-302.	1.2	134
101	Phenotypic correlates and prognostic outcomes of <scp>TET2</scp> mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American Journal of Hematology, 2020, 95, E86-E89.	2.0	3
102	A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease. American Journal of Hematology, 2020, 95, 1622-1624.	2.0	1
103	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood, 2020, 135, 381-386.	0.6	18
104	An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib. Blood, 2020, 136, 44-45.	0.6	6
105	Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study. Blood, 2020, 136, 29-31.	0.6	9
106	Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study. Blood, 2020, 136, 38-40.	0.6	1
107	Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study. Blood, 2020, 136, 47-48.	0.6	24
108	Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial. Blood, 2020, 136, 10-12.	0.6	2

#	Article	IF	Citations
109	The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 Ã— 109/L to < 100 Ã— 109/L) at Baseline. Blood, 2020, 136, 4-5.	0.6	6
110	Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients. Blood, 2020, 136, 1-3.	0.6	1
111	Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients. Blood, 2020, 136, 42-43.	0.6	8
112	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. Blood, 2020, 136, 40-41.	0.6	5
113	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood, 2020, 136, 171-182.	0.6	65
114	A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor. Blood, 2020, 136, 43-44.	0.6	0
115	Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis. Blood, 2020, 136, 52-53.	0.6	2
116	Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia. Blood, 2020, 136, 43-44.	0.6	6
117	Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis. Blood, 2020, 136, 45-46.	0.6	21
118	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Blood Cancer Journal, 2019, 9, 61.	2.8	25
119	Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. Scientific Reports, 2019, 9, 10558.	1.6	31
120	Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. Clinical Chemistry, 2019, 65, 1605-1608.	1.5	4
121	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 2019, 134, 1498-1509.	0.6	123
122	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	1.3	16
123	Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American Journal of Hematology, 2019, 94, E239-E242.	2.0	3
124	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia, 2019, 33, 1996-2005.	3.3	67
125	Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica, 2019, 104, 2391-2399.	1.7	33
126	NanoR: A user-friendly R package to analyze and compare nanopore sequencing data. PLoS ONE, 2019, 14, e0216471.	1.1	17

#	Article	IF	Citations
127	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Blood, 2019, 133, 2802-2808.	0.6	12
128	Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. American Journal of Hematology, 2019, 94, 845-852.	2.0	5
129	CircRNAs Are Here to Stay: A Perspective on the MLL Recombinome. Frontiers in Genetics, 2019, 10, 88.	1.1	19
130	Comments on preâ€fibrotic myelofibrosis and how should it be managed. British Journal of Haematology, 2019, 186, 358-360.	1.2	3
131	Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. Bioinformatics, 2019, 35, 4213-4221.	1.8	15
132	Validation of the Mayo alliance prognostic system for mastocytosis. Blood Cancer Journal, 2019, 9, 18.	2.8	6
133	Pegasus causes inherited thrombocytopenia. Blood, 2019, 134, 2000-2002.	0.6	3
134	EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica, 2019, 104, 947-954.	1.7	33
135	The JAK2 46/1 (GGCC) MPNâ€predisposing haplotype: A risky haplotype, after all. American Journal of Hematology, 2019, 94, 283-285.	2.0	3
136	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. Blood, 2019, 134, 557-557.	0.6	54
137	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. Blood, 2019, 134, 2943-2943.	0.6	4
138	Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics. Blood, 2019, 134, 1668-1668.	0.6	1
139	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. Blood, 2019, 134, 4170-4170.	0.6	2
140	Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study. Blood, 2019, 134, 704-704.	0.6	2
141	Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs). Blood, 2019, 134, 2968-2968.	0.6	4
142	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-NaÃ¯ve or were Previously Treated with Ruxolitinib. Blood, 2019, 134, 668-668.	0.6	16
143	Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib. Blood, 2019, 134, 667-667.	0.6	18
144	Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX. Blood, 2019, 134, 4165-4165.	0.6	2

#	Article	IF	Citations
145	Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis. Blood, 2019, 134, 1657-1657.	0.6	0
146	Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. Blood, 2019, 134, 2207-2207.	0.6	1
147	Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study. Blood, 2019, 134, 1662-1662.	0.6	0
148	Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome. Blood, 2019, 134, 2952-2952.	0.6	0
149	Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN). Blood, 2019, 134, 471-471.	0.6	0
150	Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis. Blood, 2019, 134, 4209-4209.	0.6	0
151	Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial. Blood, 2019, 134, 2947-2947.	0.6	0
152	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	0.6	0
153	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	3.3	415
154	A case of disseminated blastic plasmocytoid dendritic cell neoplasm. American Journal of Hematology, 2018, 93, 1433-1434.	2.0	4
155	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 2018, 32, 1631-1642.	3.3	213
156	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	1.7	31
157	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 2018, 32, 1200-1210.	3.3	101
158	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer Journal, 2018, 8, 15.	2.8	404
159	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. American Journal of Hematology, 2018, 93, 615-622.	2.0	8
160	Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic Differentiation. Stem Cells and Development, 2018, 27, 225-236.	1.1	17
161	JAK2 exon 12 mutated polycythemia vera: Mayoâ€Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. American Journal of Hematology, 2018, 93, E93-E96.	2.0	27
162	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2018, 5, e73-e81.	2.2	211

#	Article	IF	Citations
163	Essential thrombocythemia treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 2.	2.8	85
164	Polycythemia vera treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 3.	2.8	65
165	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102.	0.4	13
166	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 25.	2.8	26
167	Clonal architecture of JAK2<scp>V617F</scp> mutated cells during treatment with ruxolitinib. Hematological Oncology, 2018, 36, 357-359.	0.8	0
168	Driver mutations and prognosis in primary myelofibrosis: Mayoâ€Careggi MPN alliance study of 1,095 patients. American Journal of Hematology, 2018, 93, 348-355.	2.0	94
169	Polycythemia vera and essential thrombocythemia: algorithmic approach. Current Opinion in Hematology, 2018, 25, 112-119.	1.2	12
170	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	0.8	373
171	MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 1769-1770.	0.8	249
172	Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Blood Cancer Journal, 2018, 8, 124.	2.8	20
173	Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Blood Cancer Journal, 2018, 8, 122.	2.8	25
174	Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 103.	2.8	3
175	Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer Journal, 2018, 8, 112.	2.8	55
176	Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 104.	2.8	32
177	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89.	2.8	13
178	Role of TGF â€Î²1/miRâ€382â€5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. Molecular Oncology, 2018, 12, 2102-2123.	2.1	19
179	Response to â€œQuestions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisionsâ€•by Heidel et al.. Leukemia, 2018, 32, 2727-2728.	3.3	2
180	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	13.9	442

#	Article	IF	Citations
181	Bone marrowâ€“specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. Blood, 2018, 132, 2053-2066.	0.6	20
182	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Advances, 2018, 2, 2964-2972.	2.5	68
183	Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia, 2018, 32, 2077-2081.	3.3	30
184	Myelofibrosis Treatment Algorithm 2018. Blood Cancer Journal, 2018, 8, 72.	2.8	31
185	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer Journal, 2018, 8, 49.	2.8	30
186	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). Blood, 2018, 132, 578-578.	0.6	5
187	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. Blood, 2018, 132, 3040-3040.	0.6	1
188	Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1). Blood, 2018, 132, 690-690.	0.6	26
189	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2018, 132, 3032-3032.	0.6	6
190	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood, 2018, 132, 577-577.	0.6	39
191	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. Blood, 2018, 132, 4279-4279.	0.6	1
192	Calreticulin Ins5 and Del52 Mutations Impair Unfolded Protein and Oxidative Stress Responses in Hematopoietic Cells. Blood, 2018, 132, 4332-4332.	0.6	1
193	Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV). Blood, 2018, 132, 1753-1753.	0.6	7
194	Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study. Blood, 2018, 132, 1754-1754.	0.6	3
195	JAK2V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis. Blood, 2018, 132, 1776-1776.	0.6	0
196	Comparative Genomic and Expression Analysis of Chronic and Blast-Phase Cells in Patients with Myeloproliferative Neoplasms. Blood, 2018, 132, 1777-1777.	0.6	0
197	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. Blood, 2018, 132, 3037-3037.	0.6	0
198	Large Genomic Alterations Occurring in the Transition from Chronic to Blast Phase of Chronic Myeloproliferative Neoplasms. Blood, 2018, 132, 3028-3028.	0.6	0

#	Article	IF	Citations
199	Next-Generation Sequencing (NGS) in Childhood Myeloproliferative Diseases (MPD). Blood, 2018, 132, 3049-3049.	0.6	0
200	Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2). Blood, 2018, 132, 4281-4281.	0.6	0
201	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. Blood, 2018, 132, 1762-1762.	0.6	1
202	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. Blood, 2018, 132, 3039-3039.	0.6	0
203	Managing patients with myelofibrosis and low platelet counts. Annals of Hematology, 2017, 96, 537-548.	0.8	12
204	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leukemia Research, 2017, 56, 52-59.	0.4	22
205	No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. Haematologica, 2017, 102, e219-e221.	1.7	21
206	Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. Journal of Hematology and Oncology, 2017, 10, 54.	6.9	41
207	Diagnostic impact of the 2016 revised who criteria for polycythemia vera. American Journal of Hematology, 2017, 92, 417-419.	2.0	26
208	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Annals of Hematology, 2017, 96, 1113-1120.	0.8	68
209	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.4	25
210	A lifeâ€threatening ruxolitinib discontinuation syndrome. American Journal of Hematology, 2017, 92, 833-838.	2.0	38
211	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncology, The, 2017, 18, 88-99.	5.1	205
212	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematology,the, 2017, 4, e317-e324.	2.2	243
213	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica, 2017, 102, 85-93.	1.7	46
214	Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. European Journal of Haematology, 2017, 99, 36-41.	1.1	3
215	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	0.6	137
216	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematology,the, 2017, 4, e225-e236.	2.2	224

#	Article	IF	Citations
217	Emerging treatments for classical myeloproliferative neoplasms. Blood, 2017, 129, 693-703.	0.6	84
218	From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. Haematologica, 2017, 102, 18-29.	1.7	16
219	Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Leukemia Research, 2017, 61, 6-9.	0.4	5
220	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 2017, 130, 1768-1771.	0.6	52
221	Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S354-S355.	0.2	0
222	Traffic lights for ruxolitinib. Blood, 2017, 130, 1075-1077.	0.6	8
223	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. American Journal of Hematology, 2017, 92, 1062-1067.	2.0	33
224	Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. American Journal of Pathology, 2017, 187, 1879-1892.	1.9	17
225	A reappraisal of the benefitâ€risk profile of hydroxyurea in polycythemia vera: A propensityâ€matched study. American Journal of Hematology, 2017, 92, 1131-1136.	2.0	57
226	Gender and survival in essential thrombocythemia: A twoâ€center study of 1,494 patients. American Journal of Hematology, 2017, 92, 1193-1197.	2.0	27
227	Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clinic Proceedings, 2017, 92, 1283-1290.	1.4	53
228	CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer Journal, 2017, 7, 638.	2.8	27
229	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leukemia Research, 2017, 63, 34-40.	0.4	18
230	The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. Leukemia and Lymphoma, 2017, 58, 1481-1487.	0.6	20
231	The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, doubleâ€blind, doubleâ€dummy, symptom study (RELIEF). British Journal of Haematology, 2017, 176, 76-85.	1.2	69
232	Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. Annals of Hematology, 2017, 96, 87-92.	0.8	13
233	The effect of arterial hypertension on thrombosis in lowâ€risk polycythemia vera. American Journal of Hematology, 2017, 92, E5-E6.	2.0	45
234	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	2.0	41

#	Article	IF	Citations
235	What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?. Hematology American Society of Hematology Education Program, 2017, 2017, 480-488.	0.9	16
236	Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. International Journal of Molecular Sciences, 2017, 18, 145.	1.8	14
237	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology and Oncology, 2017, 10, 156.	6.9	210
238	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. Journal of Clinical Oncology, 2017, 35, 7001-7001.	0.8	14
239	Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation inJAK2V617Fmutated cells through PP2A/CIP2A axis. Oncotarget, 2017, 8, 96710-96724.	0.8	32
240	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 2016, 1, 21-30.	2.5	243
241	Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget, 2016, 7, 26107-26119.	0.8	136
242	Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. Journal of Experimental Medicine, 2016, 213, 1479-1496.	4.2	101
243	Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms. American Journal of Hematology, 2016, 91, E356.	2.0	13
244	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. American Journal of Hematology, 2016, 91, 918-922.	2.0	47
245	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Cancer, 2016, 122, 1888-1896.	2.0	16
246	MR Imaging in nonâ€hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. American Journal of Hematology, 2016, 91, 1062-1063.	2.0	1
247	STAT1 activation in association with JAK2 exon 12 mutations. Haematologica, 2016, 101, e15-e19.	1.7	11
248	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 2016, 101, 821-829.	1.7	140
249	Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Research, 2016, 46, 18-25.	0.4	13
250	Closing the gap: genetic landscape of MPN. Blood, 2016, 127, 276-278.	0.6	9
251	The prognostic impact of bone marrow fibrosis in primary myelofibrosis. American Journal of Hematology, 2016, 91, E454-5.	2.0	15
252	Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. American Journal of Hematology, 2016, 91, 692-699.	2.0	54

#	Article	IF	Citations
253	Changes in quality of life and diseaseâ€related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. European Journal of Haematology, 2016, 97, 192-200.	1.1	46
254	Myeloproliferative neoplasms: Morphology and clinical practice. American Journal of Hematology, 2016, 91, 430-433.	2.0	39
255	Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica, 2016, 101, 1065-1073.	1.7	130
256	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 2016, 101, 926-931.	1.7	118
257	Improving prognostic tools in systemic mastocytosis: Insights from mutations. American Journal of Hematology, 2016, 91, 867-868.	2.0	1
258	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	2.0	80
259	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. International Journal of Cancer, 2016, 138, 1657-1669.	2.3	6
260	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	0.8	56
261	Ruxolitinib is an effective treatment for <scp>CALR</scp>â€positive patients with myelofibrosis. British Journal of Haematology, 2016, 173, 938-940.	1.2	36
262	Bone Marrow-Specific Loss of ABI1 Induces Myelofibrosis through a Mechanism Involving Activation of NFÎºB. Blood, 2016, 128, 1203-1203.	0.6	1
263	Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233). Blood, 2016, 128, 3107-3107.	0.6	3
264	A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF). Blood, 2016, 128, 3110-3110.	0.6	7
265	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 3117-3117.	0.6	4
266	Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials. Blood, 2016, 128, 3118-3118.	0.6	1
267	Relationship of JAK2V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF). Blood, 2016, 128, 3131-3131.	0.6	2
268	A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results. Blood, 2016, 128, 4261-4261.	0.6	6
269	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2016, 128, 4271-4271.	0.6	5
270	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. Blood, 2016, 128, 479-479.	0.6	32

#	Article	IF	Citations
271	Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.. Journal of Clinical Oncology, 2016, 34, 7011-7011.	0.8	1
272	Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.. Journal of Clinical Oncology, 2016, 34, 7065-7065.	0.8	4
273	Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial.. Journal of Clinical Oncology, 2016, 34, 7067-7067.	0.8	1
274	ReTHINK: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.. Journal of Clinical Oncology, 2016, 34, TPS7080-TPS7080.	0.8	11
275	HDAC1 controls CIP2A transcription in human colorectal cancer cells. Oncotarget, 2016, 7, 25862-25871.	0.8	13
276	Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.. Journal of Clinical Oncology, 2016, 34, 7066-7066.	0.8	0
277	Accessible Chromatin Landscape Reveals a Proliferative Osteoprogenitor Transcriptional Program in Bone Marrow Mesenchymal Stromal Cells from Patients with Primary Myelofibrosis. Blood, 2016, 128, 3135-3135.	0.6	0
278	How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT). Blood, 2016, 128, 5472-5472.	0.6	0
279	MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis. Blood, 2016, 128, 3132-3132.	0.6	0
280	MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34+ Hematopoietic Stem/Progenitor Cells. Blood, 2016, 128, 4272-4272.	0.6	0
281	Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group. Blood, 2016, 128, 943-943.	0.6	1
282	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. Blood, 2016, 128, 5479-5479.	0.6	0
283	Prognotic Impact of Mutations in Systemic Mastocytosis. Blood, 2016, 128, 1953-1953.	0.6	0
284	Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis. Genomics Data, 2015, 5, 1-2.	1.3	5
285	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHOâ€criteria and stratified by calendar period of diagnosis. American Journal of Hematology, 2015, 90, 434-437.	2.0	19
286	JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood, 2015, 125, 3352-3353.	0.6	41
287	Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing. Biomolecular Detection and Quantification, 2015, 5, 23-29.	7.0	12
288	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Drug Design, Development and Therapy, 2015, 9, 2687.	2.0	4

#	Article	IF	Citations
289	Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells. PLoS ONE, 2015, 10, e0140445.	1.1	20
290	Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis. Haematologica, 2015, 100, 757-767.	1.7	9
291	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	1.7	203
292	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. New England Journal of Medicine, 2015, 372, 426-435.	13.9	720
293	First report ofFIP1L1-PDGFRÎ±-positive eosinophilic granulomatosis with polyangiitis : Fig. 1. Rheumatology, 2015, 54, 1751-1753.	0.9	13
294	Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. Pathology Research and Practice, 2015, 211, 341-343.	1.0	5
295	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. New England Journal of Medicine, 2015, 372, 1670-1671.	13.9	66
296	What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?. Current Hematologic Malignancy Reports, 2015, 10, 380-387.	1.2	1
297	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology, 2015, 1, 643.	3.4	362
298	Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis. Cancer Research, 2015, 75, 4753-4765.	0.4	41
299	Ruxolitinibâ€induced reversal of alopecia universalis in a patient with essential thrombocythemia. American Journal of Hematology, 2015, 90, 82-83.	2.0	56
300	Abnormal expression patterns ofWT1-as, MEG3andANRILlong non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leukemia and Lymphoma, 2015, 56, 492-496.	0.6	14
301	A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia. Blood, 2015, 126, 1602-1602.	0.6	2
302	Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. Blood, 2015, 126, 2799-2799.	0.6	6
303	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. Blood, 2015, 126, 2801-2801.	0.6	1
304	Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm. Blood, 2015, 126, 2803-2803.	0.6	2
305	Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU). Blood, 2015, 126, 2807-2807.	0.6	2
306	Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients. Blood, 2015, 126, 351-351.	0.6	1

#	Article	IF	Citations
307	Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF). Blood, 2015, 126, 4060-4060.	0.6	32
308	The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial. Blood, 2015, 126, 4070-4070.	0.6	2
309	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. Blood, 2015, 126, 4080-4080.	0.6	3
310	Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study. Blood, 2015, 126, 4087-4087.	0.6	2
311	Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes. Blood, 2015, 126, 4091-4091.	0.6	2
312	Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial. Blood, 2015, 126, 58-58.	0.6	2
313	Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results. Blood, 2015, 126, 59-59.	0.6	7
314	An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study. Blood, 2015, 126, 827-827.	0.6	17
315	Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).. Journal of Clinical Oncology, 2015, 33, LBA7006-LBA7006.	0.8	10
316	Ruxolitinib safety experience in the polycythemia vera clinical trial program.. Journal of Clinical Oncology, 2015, 33, e18082-e18082.	0.8	0
317	Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study. Blood, 2015, 126, 2804-2804.	0.6	1
318	A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis. Blood, 2015, 126, 1627-1627.	0.6	0
319	JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment. Blood, 2015, 126, 1630-1630.	0.6	0
320	Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors. Blood, 2015, 126, 353-353.	0.6	0
321	Complete Inhibition of STAT5 Phosphorylation Is Achieved By Combination of JAK1/2 and PI3K/mTOR Inhibitors in in Vitro and In Vivo MPN Models. Blood, 2015, 126, 2824-2824.	0.6	0
322	Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT). Blood, 2015, 126, 1609-1609.	0.6	6
323	Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT). Blood, 2015, 126, 4071-4071.	0.6	0
324	IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers. Blood, 2015, 126, 1615-1615.	0.6	0

#	Article	IF	Citations
325	Givinostat for the treatment of polycythemia vera. Expert Opinion on Orphan Drugs, 2014, 2, 841-850.	0.5	1
326	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	0.6	340
327	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520.	2.0	165
328	Masked polycythemia vera diagnosed according to WHO and BCSH classification. American Journal of Hematology, 2014, 89, 199-202.	2.0	64
329	Cerebral vein thrombosis in patients with <scp>P</scp>hiladelphiaâ€negative myeloproliferative neoplasms An <scp>E</scp>uropean <scp>L</scp>eukemia <scp>N</scp>et study. American Journal of Hematology, 2014, 89, E200-5.	2.0	42
330	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. British Journal of Haematology, 2014, 167, 541-546.	1.2	47
331	Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. Annals of Hematology, 2014, 93, 523-524.	0.8	4
332	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	0.6	115
333	Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. American Journal of Hematology, 2014, 89, 588-590.	2.0	75
334	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. American Journal of Hematology, 2014, 89, E121-4.	2.0	176
335	Masked polycythemia Vera (mPV): Results of an international study. American Journal of Hematology, 2014, 89, 52-54.	2.0	130
336	Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. Expert Review of Hematology, 2014, 7, 423-425.	1.0	7
337	CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. American Journal of Hematology, 2014, 89, 453-456.	2.0	34
338	Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood, 2014, 123, 1552-1555.	0.6	346
339	Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. American Journal of Hematology, 2014, 89, 438-442.	2.0	9
340	Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. American Journal of Hematology, 2014, 89, 306-309.	2.0	50
341	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. Leukemia Research, 2014, 38, 155-160.	0.4	28
342	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 2014, 99, 292-298.	1.7	38

#	Article	IF	Citations
343	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood, 2014, 124, 1183-1191.	0.6	135
344	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 2014, 124, 2507-2513.	0.6	575
345	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 2014, 123, 3803-3810.	0.6	79
346	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	0.6	105
347	Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood, 2014, 123, 1833-1835.	0.6	95
348	How I treat polycythemia vera. Blood, 2014, 124, 3212-3220.	0.6	75
349	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood, 2014, 124, 3021-3023.	0.6	112
350	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood, 2014, 124, 2611-2612.	0.6	79
351	Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Haematologica, 2014, 99, 797-801.	1.7	6
352	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. Blood, 2014, 124, 1824-1824.	0.6	9
353	Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea. Blood, 2014, 124, 1840-1840.	0.6	2
354	Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea. Blood, 2014, 124, 1847-1847.	0.6	14
355	Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients. Blood, 2014, 124, 1848-1848.	0.6	2
356	Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study). Blood, 2014, 124, 1849-1849.	0.6	4
357	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. Blood, 2014, 124, 3163-3163.	0.6	1
358	The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF). Blood, 2014, 124, 3168-3168.	0.6	5
359	Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial. Blood, 2014, 124, 3181-3181.	0.6	1
360	A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group. Blood, 2014, 124, 3192-3192.	0.6	1

#	Article	IF	Citations
361	Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update. Blood, 2014, 124, 3197-3197.	0.6	7
362	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	0.6	47
363	Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis. Blood, 2014, 124, 406-406.	0.6	27
364	HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF). Blood, 2014, 124, 710-710.	0.6	27
365	Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis. Blood, 2014, 124, 711-711.	0.6	6
366	Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood, 2014, 124, 712-712.	0.6	8
367	A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.. Journal of Clinical Oncology, 2014, 32, 7022-7022.	0.8	3
368	Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial. Journal of Clinical Oncology, 2014, 32, 7026-7026.	0.8	12
369	Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients. Blood, 2014, 124, 633-633.	0.6	0
370	Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial. Blood, 2014, 124, 3201-3201.	0.6	8
371	Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results. Blood, 2014, 124, 709-709.	0.6	0
372	C-Myb Restrains Megakaryopoiesis through the Hsa-MiR-486-3p-Driven Down-Regulation of C-Maf. Blood, 2014, 124, 5124-5124.	0.6	0
373	Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression. Blood, 2014, 124, 3187-3187.	0.6	0
374	JAK2V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib. Blood, 2014, 124, 3185-3185.	0.6	0
375	A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. Blood, 2014, 124, 3188-3188.	0.6	0
376	Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia. Blood, 2014, 124, 404-404.	0.6	0
377	A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis. Blood, 2014, 124, 1853-1853.	0.6	0
378	A phase II study of <scp>G</scp>ivinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. British Journal of Haematology, 2013, 161, 688-694.	1.2	109

#	Article	IF	Citations
379	Struggling with myelofibrosis-associated anemia. Leukemia Research, 2013, 37, 1429-1431.	0.4	8
380	Preclinical Models for Drug Selection in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2013, 8, 317-324.	1.2	3
381	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	0.6	286
382	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 2013, 122, 4047-4053.	0.6	383
383	Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S307-S309.	0.2	45
384	The burden of symptoms in myelofibrosis: From patient-reported outcomes to health economics. Leukemia Research, 2013, 37, 855-856.	0.4	3
385	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	3.3	653
386	No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis. Haematologica, 2013, 98, e83-e84.	1.7	4
387	Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. Haematologica, 2013, 98, e101-e102.	1.7	24
388	JAK2 Mutation-Related Disease and Thrombosis. Seminars in Thrombosis and Hemostasis, 2013, 39, 496-506.	1.5	40
389	The <scp>ERCC2 G</scp>ln/<scp>G</scp>ln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. British Journal of Haematology, 2013, 162, 424-427.	1.2	4
390	Coâ€targeting the PI3K/<scp>mTOR</scp> and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. Journal of Cellular and Molecular Medicine, 2013, 17, 1385-1396.	1.6	96
391	Healthâ€related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 2013, 162, 229-239.	1.2	75
392	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. New England Journal of Medicine, 2013, 368, 22-33.	13.9	664
393	Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood, 2013, 121, 360-368.	0.6	102
394	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 2013, 121, 4778-4781.	0.6	219
395	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	0.6	3
396	Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II. Blood, 2013, 122, 107-107.	0.6	2

#	Article	IF	Citations
397	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. Blood, 2013, 122, 1582-1582.	0.6	1
398	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. Blood, 2013, 122, 1583-1583.	0.6	4
399	Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). Blood, 2013, 122, 393-393.	0.6	22
400	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. Blood, 2013, 122, 394-394.	0.6	29
401	A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Postâ€"Polycythemia Vera MF (PPV-MF), Or Postâ€"Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose. Blood, 2013, 122, 4045-4045.	0.6	13
402	Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts. Blood, 2013, 122, 4066-4066.	0.6	1
403	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. Blood, 2013, 122, 4067-4067.	0.6	6
404	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. Blood, 2013, 122, 4068-4068.	0.6	10
405	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). Blood, 2013, 122, 4070-4070.	0.6	15
406	Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). Blood, 2013, 122, 661-661.	0.6	13
407	The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients. Blood, 2013, 122, LBA-2-LBA-2.	0.6	1
408	mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms. PLoS ONE, 2013, 8, e54826.	1.1	80
409	Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. PLoS ONE, 2013, 8, e77819.	1.1	9
410	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. Blood, 2013, 122, 1587-1587.	0.6	3
411	Thrombosis History and Relationship With Low Thrombocytosis, Leukocytosis, and Other Characteristics At Diagnosis In 977 Essential Thrombocythemia Patients A Multivariate Analysis Of The Registro Italiano Trombocitemie (RIT). Blood, 2013, 122, 2829-2829.	0.6	0
412	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. Blood, 2013, 122, 1600-1600.	0.6	0
413	Masked Polycythemia Vera (mPV): Results Of An International Study. Blood, 2013, 122, 1581-1581.	0.6	0
414	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. Blood, 2013, 122, 4099-4099.	0.6	0

#	Article	IF	Citations
415	Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis. Blood, 2013, 122, 4058-4058.	0.6	0
416	The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms. Blood, 2013, 122, 1599-1599.	0.6	3
417	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Therapeutic Advances in Hematology, 2012, 3, 341-354.	1.1	50
418	Improving Survival Trends in Primary Myelofibrosis: An International Study. Journal of Clinical Oncology, 2012, 30, 2981-2987.	0.8	105
419	BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. Future Oncology, 2012, 8, 575-593.	1.1	4
420	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Journal of Clinical Oncology, 2012, 30, 4098-4103.	0.8	344
421	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood, 2012, 119, 2239-2241.	0.6	90
422	Risk of second cancers in chronic myeloproliferative neoplasms. Blood, 2012, 119, 3861-3862.	0.6	14
423	A prognostic model to predict survival in 867 World Health Organizationâ€“defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood, 2012, 120, 1197-1201.	0.6	222
424	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 2012, 366, 787-798.	13.9	1,543
425	JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood, 2012, 120, 2704-2707.	0.6	94
426	Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells. Blood, 2012, 119, e120-e130.	0.6	34
427	Clinical significance of genetic aberrations in secondary acute myeloid leukemia. American Journal of Hematology, 2012, 87, 1010-1016.	2.0	67
428	Development and validation of an International Prognostic Score of thrombosis in World Health Organizationâ€“essential thrombocythemia (IPSET-thrombosis). Blood, 2012, 120, 5128-5133.	0.6	461
429	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood, 2012, 120, 569-571.	0.6	69
430	Hydroxyureaâ€related toxicity in 3,411 patients with Ph'â€negative MPN. American Journal of Hematology, 2012, 87, 552-554.	2.0	105
431	Leukocytosis as an important risk factor for arterial thrombosis in WHOâ€defined early/prefibrotic myelofibrosis: An international study of 264 patients. American Journal of Hematology, 2012, 87, 669-672.	2.0	49
432	JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leukemia Research, 2012, 36, e7-e9.	0.4	17

#	Article	IF	Citations
433	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. American Journal of Hematology, 2012, 87, 203-204.	2.0	29
434	Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. American Journal of Hematology, 2012, 87, 245-250.	2.0	107
435	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. Blood, 2012, 120, 1731-1731.	0.6	2
436	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. Blood, 2012, 120, 1748-1748.	0.6	1
437	Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 Ã— 109/L and 99 Ã— 109/L. Blood, 2012, 120, 177-177.	0.6	7
438	A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). Blood, 2012, 120, 4-4.	0.6	3
439	Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF). Blood, 2012, 120, 801-801.	0.6	33
440	Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT). Blood, 2012, 120, 802-802.	0.6	12
441	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. Blood, 2012, 120, 804-804.	0.6	6
442	Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy â€“ Second-Line Options. , 2012, , 119-129.		0
443	Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.. Blood, 2012, 120, 2854-2854.	0.6	0
444	Role of the Somatic Mutation Rate in Patients with Classical Myeloproliferative Neoplasms (MPN) with and without Other Neoplasms. Blood, 2012, 120, 5055-5055.	0.6	0
445	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. Blood, 2012, 120, 1726-1726.	0.6	4
446	Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis. Blood, 2012, 120, 431-431.	0.6	19
447	Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease. Blood, 2012, 120, 708-708.	0.6	0
448	Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. Blood, 2012, 120, 2852-2852.	0.6	0
449	Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort. Blood, 2012, 120, 1729-1729.	0.6	1
450	Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. Blood, 2012, 120, 2849-2849.	0.6	0

#	Article	IF	Citations
451	Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood, 2011, 117, 2813-2816.	0.6	190
452	JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Therapeutic Advances in Hematology, 2011, 2, 21-32.	1.1	82
453	The dominant negative Î² isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood, 2011, 118, 425-436.	0.6	47
454	Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. Blood, 2011, 117, 6923-6927.	0.6	26
455	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	0.6	280
456	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	0.6	144
457	Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood, 2011, 117, 5857-5859.	0.6	376
458	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	0.6	242
459	Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood, 2011, 118, 3445-3446.	0.6	32
460	Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leukemia Research, 2011, 35, 1557-1563.	0.4	32
461	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	0.8	724
462	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood, 2011, 118, 167-176.	0.6	153
463	The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. Annals of Hematology, 2011, 90, 365-366.	0.8	6
464	Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy, 2011, 12, 1597-1611.	0.9	25
465	Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica, 2011, 96, 1398-402.	1.7	27
466	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica, 2011, 96, 315-318.	1.7	160
467	Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. Journal of Clinical Oncology, 2011, 29, 3179-3184.	0.8	441
468	Management of Myelofibrosis. Hematology American Society of Hematology Education Program, 2011, 2011, 222-230.	0.9	48

#	Article	IF	Citations
469	A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf		
470	A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy. Blood, 2011, 118, 1748-1748.	0.6	9
471	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. Blood, 2011, 118, 1750-1750.	0.6	2
472	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. Blood, 2011, 118, 277-277.	0.6	7
473	Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study. Blood, 2011, 118, 279-279.	0.6	13
474	Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis. Blood, 2011, 118, 2811-2811.	0.6	4
475	Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,. Blood, 2011, 118, 3835-3835.	0.6	7
476	Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,. Blood, 2011, 118, 3852-3852.	0.6	1
477	Health-Related Quality of Life and Symptoms in Myelofibrosis Patients Treated with Ruxolitinib Versus Best Available Therapy. Blood, 2011, 118, 795-795.	0.6	3
478	Distinct Genetic Lesions Drive Leukemogenesis in Secondary Acute Myeloid Leukemia,. Blood, 2011, 118, 3559-3559.	0.6	15
479	First Achievements of MPN&MPNr-EuroNet (COST Action BM0902), a New European Network Dedicated to the Diagnosis of Myeloproliferative Neoplasms and Hereditary Erythrocytosis and Thrombocytosis. Blood, 2011, 118, 2809-2809.	0.6	6
480	Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2010, 85, 97-100.	2.0	48
481	Advances in understanding and management of polycythemia vera. Current Opinion in Oncology, 2010, 22, 636-641.	1.1	8
482	Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica, 2010, 95, 2153-2156.	1.7	19
483	Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica, 2010, 95, 833-836.	1.7	34
484	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood, 2010, 116, 1051-1055.	0.6	56
485	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica, 2010, 95, 1435-1438.	1.7	41
486	Two routes to leukemic transformation after a JAK2 mutationâ€“positive myeloproliferative neoplasm. Blood, 2010, 115, 2891-2900.	0.6	269

#	Article	IF	Citations
487	Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Annals of Hematology, 2010, 89, 141-146.	0.8	39
488	Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. Annals of Hematology, 2010, 89, 745-746.	0.8	1
489	JAK2 Mutation and Thrombosis in the Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2010, 5, 22-28.	1.2	20
490	Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Internal and Emergency Medicine, 2010, 5, 177-184.	1.0	51
491	JAK2V617F mutation persists in blasts and mature cells of transformedJAK2V617Fâ€positiveâ€myeloproliferative neoplasia: A European leukemia net (ENL) study. American Journal of Hematology, 2010, 85, 383-386.	2.0	2
492	Phase I/II study of singleâ€agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology, 2010, 85, 616-619.	2.0	18
493	Evidence for organâ€specific stem cell microenvironments. Journal of Cellular Physiology, 2010, 223, 460-470.	2.0	6
494	CXCR4â€independent rescue of the myeloproliferative defect of the gata1^{low} myelofibrosis mouse model by AplidinÂ®. Journal of Cellular Physiology, 2010, 225, 490-499.	2.0	16
495	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	1.2	144
496	A pilot study of the Histoneâ€Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 2010, 150, 446-455.	1.2	202
497	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS ONE, 2010, 5, e15277.	1.1	30
498	From Palliation to Targeted Therapy in Myelofibrosis. New England Journal of Medicine, 2010, 363, 1180-1182.	13.9	17
499	The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood, 2010, 115, 4517-4523.	0.6	93
500	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood, 2010, 116, 2857-2858.	0.6	153
501	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 2010, 115, 1703-1708.	0.6	805
502	Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 2010, 115, 778-782.	0.6	216
503	Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT). Blood, 2010, 116, 1973-1973.	0.6	2
504	Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). Blood, 2010, 116, 313-313.	0.6	33

#	Article	IF	Citations
505	A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results. Blood, 2010, 116, 314-314.	0.6	7
506	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. Blood, 2010, 116, 4105-4105.	0.6	4
507	Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients. Blood, 2010, 116, 457-457.	0.6	6
508	Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. F1000 Medicine Reports, 2010, 2, .	2.9	3
509	Characterization of Targets of Plitidepsin In JAK2V617F-Mutated Cells From Myeloproliferative Neoplasms. Blood, 2010, 116, 4093-4093.	0.6	0
510	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients. Blood, 2010, 116, 4095-4095.	0.6	5
511	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	0.6	229
512	Increased Differentiation of Dermal Mast Cells in Mice Lacking the Mpl Gene. Stem Cells and Development, 2009, 18, 1081-1092.	1.1	3
513	Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2068-2073.	1.1	100
514	JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica, 2009, 94, 144-146.	1.7	35
515	Advances in Understanding and Management of Myeloproliferative Neoplasms. Ca-A Cancer Journal for Clinicians, 2009, 59, 171-191.	157.7	170
516	Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. Journal of Cellular and Molecular Medicine, 2009, 13, 1437-1450.	1.6	23
517	JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera. Experimental Hematology, 2009, 37, 1016-1021.	0.2	89
518	Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: The crucial role of PTEN. Experimental Hematology, 2009, 37, 1176-1185.e21.	0.2	17
519	A short lowâ€dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. British Journal of Haematology, 2009, 147, 681-685.	1.2	8
520	Removal of the Spleen in Mice Alters the Cytokine Expression Profile of the Marrow Microâ€environment and Increases Bone Formation. Annals of the New York Academy of Sciences, 2009, 1176, 77-86.	1.8	9
521	How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis. Leukemia Research, 2009, 33, 1581-1583.	0.4	18
522	JAK2V617F mutation screening in patients with retinal vein thrombosis or recurrent fetal loss. Thrombosis Research, 2009, 124, 377-378.	0.8	1

#	Article	IF	Citations
523	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2009, 113, 2895-2901.	0.6	1,110
524	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 2009, 114, 1477-1483.	0.6	196
525	Treatment options for essential thrombocythemia and polycythemia vera. Expert Review of Hematology, 2009, 2, 41-55.	1.0	6
526	Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation. Blood, 2009, 114, 2107-2120.	0.6	26
527	The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica, 2009, 94, 1537-1545.	1.7	58
528	The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.. Blood, 2009, 114, 2914-2914.	0.6	8
529	RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET) Tj ETQq1 1 0.784314 rgBT /Ove	0.6	78
530	FLT3-Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis.. Blood, 2009, 114, 963-963.	0.6	1
531	Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. Leukemia Research, 2008, 32, 516-517.	0.4	17
532	Thrombopoietin Inhibits Murine Mast Cell Differentiation. Stem Cells, 2008, 26, 912-919.	1.4	20
533	Hypermethylation ofCXCR4Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. Stem Cells, 2008, 26, 1920-1930.	1.4	91
534	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia, 2008, 22, 1299-1307.	3.3	273
535	Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1low mouse model of the disease. Experimental Hematology, 2008, 36, 158-171.	0.2	50
536	Animal Models of Myelofibrosis. , 2008, , 713-723.		1
537	A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2008, 10, 435-441.	1.2	47
538	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica, 2008, 93, 41-48.	1.7	146
539	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia. Journal of Clinical Oncology, 2008, 26, 2732-2736.	0.8	169
540	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 2008, 93, 372-380.	1.7	316

#	Article	IF	Citations
541	Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations. Haematologica, 2008, 93, 972-976.	1.7	25
542	Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood, 2008, 111, 666-671.	0.6	106
543	JAK2: how many faces in MPDs?. Blood, 2008, 111, 2499-2499.	0.6	2
544	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood, 2008, 112, 844-847.	0.6	216
545	Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood, 2008, 112, 3135-3137.	0.6	100
546	A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms. Blood, 2008, 112, 100-100.	0.6	28
547	Dysregulated Expression of MicroRNA-16 Contributes to Abnormal Erythropoiesis in Patients with Polycythemia Vera. Blood, 2008, 112, 179-179.	0.6	2
548	B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica, 2007, 92, 258-259.	1.7	26
549	Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica, 2007, 92, 597-604.	1.7	31
550	The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. Blood, 2007, 109, 1460-1471.	0.6	48
551	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 2007, 110, 840-846.	0.6	419
552	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110, 1092-1097.	0.6	808
553	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 2007, 110, 4030-4036.	0.6	233
554	Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. Blood, 2007, 110, 4620-4621.	0.6	11
555	Thrombocytosis and Thrombosis. Hematology American Society of Hematology Education Program, 2007, 2007, 363-370.	0.9	73
556	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells, Molecules, and Diseases, 2007, 38, 280-286.	0.6	60
557	Insights into JAK2-V617F mutation in CML. Lancet Oncology, The, 2007, 8, 864-866.	5.1	50
558	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 2007, 31, 737-740.	0.4	288

#	Article	IF	Citations
559	Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia, 2007, 21, 1952-1959.	3.3	328
560	The haematocrit and platelet target in polycythemia vera. British Journal of Haematology, 2007, 136, 249-259.	1.2	162
561	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. British Journal of Haematology, 2007, 137, 244-247.	1.2	153
562	MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Experimental Hematology, 2007, 35, 1708.e1-1708.e12.	0.2	71
563	Role of Thrombopoietin in Mast Cell Differentiation. Annals of the New York Academy of Sciences, 2007, 1106, 152-174.	1.8	8
564	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). Stem Cells, 2007, 25, 165-173.	1.4	111
565	Circulating Endothelial Progenitor Cells Are Increased in Patients with Myelofibrosis and Do Not Harbor V617F JAK-2 or W515L MPL Mutations. Blood, 2007, 110, 1535-1535.	0.6	1
566	A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis.. Blood, 2007, 110, 3540-3540.	0.6	39
567	Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. British Journal of Haematology, 2006, 132, 652-654.	1.2	11
568	A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia, 2006, 20, 1055-1060.	3.3	68
569	Differential Amplification of Murine Bipotent Megakaryocytic/Erythroid Progenitor and Precursor Cells During Recovery from Acute and Chronic Erythroid Stress. Stem Cells, 2006, 24, 337-348.	1.4	25
570	The Hypomorphic Gata1low Mutation Alters the Proliferation/Differentiation Potential of the Common Megakaryocytic-Erythroid Progenitor.. Blood, 2006, 108, 2549-2549.	0.6	1
571	Thrombotic and Hemorrhagic Complications after Surgery in Patients with Essential Thrombocythemia and Polycythemia Vera.. Blood, 2006, 108, 2693-2693.	0.6	1
572	Influence of the Jak2V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera.. Blood, 2006, 108, 5-5.	0.6	14
573	Murine Mast Cells Express Mpl, the Thrombopoietin Receptor, and Thrombopoietin Is a Potent Regulator of Mast Cell Differentiation.. Blood, 2006, 108, 1335-1335.	0.6	0
574	A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-Î²1 in the development of myelofibrosis. Blood, 2005, 105, 3493-3501.	0.6	103
575	Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds. Blood, 2005, 106, 4102-4113.	0.6	32
576	Role of GATA-1 in Normal and Neoplastic Hemopoiesis. Annals of the New York Academy of Sciences, 2005, 1044, 142-158.	1.8	20

#	Article	IF	Citations
577	Pathogenesis of Myelofibrosis With Myeloid Metaplasia: Lessons From Mouse Models of the Disease. Seminars in Oncology, 2005, 32, 365-372.	0.8	13
578	Isolation of TPO-dependent subclones from the multipotent 32D cell line. Blood Cells, Molecules, and Diseases, 2005, 35, 241-252.	0.6	4
579	Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis. American Journal of Pathology, 2005, 167, 849-858.	1.9	62
580	Pericyte Coverage of Abnormal Blood Vessels in Myelofibrosis Bone Marrows.. Blood, 2005, 106, 4936-4936.	0.6	0
581	The Ultrastructure Features of the Advanced Stages of Fibrosis in GATA-1low Mice Are Similar to Those Found in Wound Healing.. Blood, 2005, 106, 3514-3514.	0.6	0
582	PRV-1 , erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. British Journal of Haematology, 2004, 127, 214-219.	1.2	21
583	Impaired GATA-1 expression and myelofibrosis in an animal model. Pathologie Et Biologie, 2004, 52, 275-279.	2.2	13
584	Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice. Blood, 2004, 104, 3573-3580.	0.6	107
585	Increased and Pathological Emperipolesis of Neutrophils within Megakaryocytes Associated with Myelofibrosis in GATA-1LowMice.. Blood, 2004, 104, 2430-2430.	0.6	1
586	Thrombopoietin Regulates Proliferation and Maturation of Murine Mast Cells.. Blood, 2004, 104, 1707-1707.	0.6	0
587	Effects of the Genetic Background on the Myelofibrosis Induced by the GATA-1Low Mutation.. Blood, 2004, 104, 2433-2433.	0.6	0
588	GATA-1 as a Regulator of Mast Cell Differentiation Revealed by the Phenotype of the GATA-1low Mouse Mutant. Journal of Experimental Medicine, 2003, 197, 281-296.	4.2	203
589	Robust Levels of Long-Term Multilineage Reconstitution in the Absence of Stem Cell Self-Replication inW/WvMice Transplanted with Purified Stem Cells. Journal of Hematotherapy and Stem Cell Research, 2003, 12, 409-424.	1.8	3
590	Specific PAF antagonist WEBâ€2086 induces terminal differentiation of murine and human leukemia cells. FASEB Journal, 2002, 16, 733-735.	0.2	19
591	Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1low mice). Blood, 2002, 100, 1123-1132.	0.6	215
592	Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1low mice). Blood, 2001, 97, 3040-3050.	0.6	62
593	Selective ex vivo expansion of cytomegalovirus-specific CD4+ and CD8+ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide. British Journal of Haematology, 2001, 113, 479-482.	1.2	21
594	Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice. Blood, 2000, 95, 2559-2568.	0.6	81

#	Article	IF	Citations
595	Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice. Blood, 2000, 95, 2559-2568.	0.6	6
596	Constitutive muscarinic receptors are involved in the growth and differentiation of friend erythroleukemia cells. Journal of Cellular Physiology, 1999, 178, 333-340.	2.0	2
597	Increased expression of the distal, but not of the proximal,Gata1 transcripts during differentiation of primary erythroid cells. , 1999, 180, 390-401.		22
598	Erythropoietin upregulates the expression of its own receptor in TF-1 cell line. Leukemia Research, 1998, 22, 145-151.	0.4	32
599	Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias. British Journal of Haematology, 1998, 102, 1335-1337.	1.2	17
600	Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. British Journal of Haematology, 1998, 103, 610-617.	1.2	54
601	An erythroid and megakaryocytic common precursor cell line (B1647) expressing both câ€mpl and erythropoietin receptor (Epoâ€R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo). British Journal of Haematology, 1997, 98, 549-559.	1.2	19
602	Constitutive and inducible expression of megakaryocyte-specific genes in Friend erythroleukaemia cells. British Journal of Haematology, 1997, 99, 500-508.	1.2	17
603	Growth factor receptor expression during in vitro differentiation of partially purified populations containing murine stem cells. Journal of Cellular Physiology, 1997, 171, 343-356.	2.0	29
604	The Humoral Regulation of Normal and Pathologic Erythropoiesis. E&M Endocrinology and Metabolism, 1993, , 47-70.	0.1	0
605	Humoral regulation of megakaryocytopoiesis. Biotherapy (Dordrecht, Netherlands), 1990, 2, 375-383.	0.7	3
606	The Effect of Picotamide on Platelet Function in Patients with Myeloproliferative Disorders. Thrombosis and Haemostasis, 1990, 63, 525-526.	1.8	2
607	Recombinant human erythropoietin has little influence on megakaryocytopoiesis in mice. British Journal of Haematology, 1989, 71, 463-468.	1.2	20
608	A dot assay for the erythropoietin receptor using human recombinant 125I-erythropoietin. Analytical Biochemistry, 1989, 182, 182-186.	1.1	1
609	Megakaryocyte progenitors in the bone marrow and peripheral blood of patients with myeloproliferative diseases. American Journal of Hematology, 1987, 25, 371-376.	2.0	25
610	Beta-thromboglobulin content in megakaryocytes of patients with myeloproliferative diseases. Thrombosis Research, 1986, 43, 367-374.	0.8	5
611	The newly diagnosed patient with polycythemia vera. , 0, , 64-69.		0